MGMT and glioblastoma: For example, the landmark EORTC/NCIC phase III trial by Stupp et al. [11], which investigated the addition of TMZ to radiation therapy (RT) in newly diagnosed GBM patients, established a significant survival benefit of TMZ, but only in patients with MGMT-negative tumors.